Search clinical trials for: Patients with high risk adenocarcinoma of the prostate

Total 463244 results

University of Chicago

Recruiting

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Prostate Cancer | Prostate Adenocarcinoma

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score

Prostate Adenocarcinoma

United States, Canada
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Prostate Adenocarcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

United States, Canada
Centre Georges Francois Leclerc

Recruiting

Study Evaluating the Efficacy and the Tolerance of Pelvic-prostatic Hypo-fractionated Radiotherapy Followed by Boost in Patients With Prostate Adenocarcinoma Adverse Intermediate Risk or High Localized Risk (SHORT)

To Evaluate the Rate of Digestive and Urinary Toxicity

France
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Recruiting

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma

United States
Memorial Sloan Kettering Cancer Center
Ferring Pharmaceuticals

Active, not recruiting

Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer

Prostate Cancer | Prostatic Adenocarcinoma

United States
NRG Oncology
National Cancer Institute (NCI)

Suspended

Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer (NADIR)

Prostate Adenocarcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

Canada, United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | ERBB2 Gene Amplification | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage... and other conditions

United States, Puerto Rico
Jonsson Comprehensive Cancer Center

Active, not recruiting

Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer

Stage III Prostate Cancer | Adenocarcinoma of the Prostate

United States
University Health Network, Toronto

Completed

Intensity Modulated Radiation Therapy (IMRT) Pelvic Nodes Prostate

Adenocarcinoma of the Prostate

Canada
Sidney Kimmel Cancer Center at Thomas Jefferson...
Astellas Pharma Inc; Medivation, Inc.

Active, not recruiting

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Recurrent Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIB Prostate Cancer

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Active, not recruiting

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Prostate Cancer

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical... and other collaborators

Active, not recruiting

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Prostate Cancer

United States, Canada
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Stage III Prostate Adenocarcinoma AJCC v7 | Stage II Prostate Adenocarcinoma AJCC v7 | Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma

United States
University of Texas Southwestern Medical Center
National Cancer Institute (NCI)

Withdrawn

Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery

Prostate Cancer

United States
Gary Onik MD

Completed

A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen. (NIRPA)

Adenocarcinoma

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

Prostate Cancer

United States, Canada
AstraZeneca

Completed

Non-Interventional Study PREVENT (PREVENT)

Postoperative or Postradiation Adjuvant Androgen Deprivation Therapy in Locally Advanced Prostate Cancer (High and Very High Risk) Patients

Russian Federation
Case Comprehensive Cancer Center

Completed

Enzalutamide in Patients With High-risk Prostate Cancer

Adenocarcinoma of the Prostate

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer

Prostate Cancer

United States
University of Nebraska
National Cancer Institute (NCI)

Completed

Intensity-Modulated Radiation Therapy, Docetaxel, and Hormone Therapy in Treating Patients With High-Risk Locally Advanced Prostate Cancer With Pelvic Lymph Node Metastasis

Prostate Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Sanofi

Completed

Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer (NRR)

Prostate Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Withdrawn

Mitoxantrone Following Surgery in Treating Patients With Prostate Cancer at High Risk for Recurrence

Prostate Cancer
Mary-Ellen Taplin, MD
Sanofi; Beth Israel Deaconess Medical Center; Genentech, Inc.; Duke University

Completed

Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy

Prostate Cancer | Adenocarcinoma of the Prostate

United States
Myrexis Inc.

Unknown

R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence

Prostate Cancer

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse

Prostate Cancer

United States
Chang Gung Memorial Hospital
Ministry of Health and Welfare, Taiwan

Recruiting

Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma

High Risk of Recurrence

Taiwan
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence

China
Region Skane

Recruiting

Tumor-directed Radiation Therapy for Patients With the Highest Risk Category of Localized Prostate Cancer

Prostate Cancer

Sweden
University of Kansas Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Stage III Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

United States
FutureChem

Recruiting

[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer

High Risk Prostate Carcinoma

Korea, Republic of
Zhejiang Cancer Hospital

Recruiting

Lenvatinib Combined With Tislelizumab and TACE Applied as Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma With High-risk Recurrence Factors

Hepatocellular Carcinoma | Oxaliplatin | TACE | Lenvatinib | Tislelizumab | Pharmorubicin

China
Catalysis SL
Atika Pharma S.L.

Recruiting

Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)

Papilloma Viral Infection | CIN1 | LSIL, Low Grade Squamous Intraepithelial Lesion

Spain
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

Prostate Adenocarcinoma | Stage IIIB Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
Xian-Janssen Pharmaceutical Ltd.

Not yet recruiting

Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study) (ARES)

Prostate Cancer | Biochemical Recurrence | High Risk

China
Federation Francophone de Cancerologie Digestive

Not yet recruiting

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy (TRIPLET)

Metastatic Cancer | Metastatic Tumor | HCC - Hepatocellular Carcinoma

France
Washington University School of Medicine
Varian Medical Systems

Recruiting

Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer

Prostate Cancer | Cancer of the Prostate

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

Hepatocellular Carcinoma

United States
Monte Rosa Therapeutics, Inc

Recruiting

Study of Oral MRT-2359 in Selected Cancer Patients

NSCLC | Prostate Cancer | SCLC | DLBCL | High Grade Neuroendocrine Cancer | L-MYC and N-MYC Amplified Solid Tumors | NSCLC With High or Low L-MYC or N-MYC Expression | HR-positive, HER2-negative Breast Cancer

United States, Canada
Rana McKay, MD
University of California, San Diego; AstraZeneca

Recruiting

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations (NePtune)

Prostate Cancer | BRCA1 Mutation | BRCA2 Mutation | Prostatic Adenocarcinoma | High-Risk Cancer

United States
Sven Löffeler
Oslo University Hospital; Klinbeforsk

Recruiting

Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer (GrandP/SPCG19)

Prostate Cancer

Norway, Denmark, Finland
West China Hospital

Recruiting

A Phase II Clinical Study of Stereotactic Radiation Therapy in Patients With High-risk Prostate Cancer

Prostate Cancer | Efficacy | Safety | Stereotactic Body Radiotherapy | High-risk

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Melanoma | Sarcoma | Acute Myeloid Leukemia | Stage I Uterine Corpus Cancer AJCC v7 | Stage II Uterine Corpus Cancer AJCC v7 | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Stage III Pancreatic... and other conditions

United States
Fudan University

Recruiting

HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection

Hepatocarcinoma

China
Chinese PLA General Hospital
Immunotech Applied Science Ltd.

Recruiting

Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection

Hepatocellular Carcinoma (HCC)

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis

Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi

China
National Cancer Institute (NCI)

Recruiting

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma | Resectable Pancreatic Acinar Cell Carcinoma | Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenosquamous Carcinoma | Resectable Pancreatic Carcinoma

United States
Fudan University

Recruiting

Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence

Cholangiocarcinoma, Intrahepatic

China

Search clinical trials for: Patients with high risk adenocarcinoma of the prostate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations